- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6425
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Roche Products
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Association of Cancer Physicians
- British Oncology Pharmacy Association
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
- National Institute for Health & Care Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 April 2025 | Invitation to participate |
| 16 January 2025 - 13 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6425 |
| 16 January 2025 | In progress. Scoping commenced. |
| 28 February 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual